We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ABOS market cap is 99.13M. The company's latest EPS is USD -0.8717 and P/E is -1.88.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.04M | -18.49M | -17.77M | -24.38M | -32.27M |
| Net Income | -12.96M | -16.5M | -14.87M | -20.54M | -29.77M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.7M | 1.44M | 0 | 0 | 0 |
| Operating Income | -7.81M | -7.91M | -19.58M | -45.24M | -61.14M |
| Net Income | -7.69M | -7.33M | -100.61M | -42.86M | -52.37M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 286.37M | 310.13M | 300.97M | 288.91M | 266.98M |
| Total Liabilities | 6.1M | 43.15M | 38.93M | 44.97M | 49.77M |
| Total Equity | 280.27M | 266.97M | 262.03M | 243.95M | 217.2M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 7.32M | 44.43M | 230.33M | 196.59M | 310.13M |
| Total Liabilities | 1.34M | 6.37M | 5.15M | 7.81M | 43.15M |
| Total Equity | -11.42M | -18.59M | 225.18M | 188.78M | 266.97M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -34.75M | -43.06M | -17.86M | -34.4M | -59M |
| Investing | -122.86M | -171.67M | -9.2M | 28.5M | 18.36M |
| Financing | 122.62M | 151.75M | 7.11M | 6.98M | 6.94M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.82M | -7.45M | -17.96M | -35.15M | -43.06M |
| Investing | N/A | N/A | -104.12M | 39.19M | -171.67M |
| Financing | 6.24M | 44.68M | 200.47M | 3.91M | 151.75M |
| Market Cap | 99.13M |
| Price to Earnings Ratio | -1.88 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.47 |
| Price to Book Ratio | 0.37 |
| Dividend Yield | - |
| Shares Outstanding | 60.08M |
| Average Volume (1 week) | 555.37k |
| Average Volume (1 Month) | 364.14k |
| 52 Week Change | -51.33% |
| 52 Week High | 5.09 |
| 52 Week Low | 1.53 |
| Spread (Intraday) | 0.02 (1.2%) |
| Company Name | Acumen Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.acumenpharm.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
